Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 201–300 of 810
Eggert, S., Thomas, C., Kins, S., & Hermey, G. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0806-x · Cited by 81
“brains and knockdown of retromer elements in cell culture led to increased Aβ production, while overexpression of retromer elements decreased Aβ levels [167].”
BackgroundGopalan, D., Pandey, A., Udupa, N., & Mutalik, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.034 · Cited by 72
Gray, S. C., Kinghorn, K. J., & Woodling, N. S. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272571 · Cited by 74
“ApoE is synthesized by astrocytes and microglia, and lipidated by ATP-binding cassette A1 to form lipoprotein particles (Holtzman et al., 2012).”
BackgroundAPOE4 confers transcriptomic and functional alterations to primary mouse microglia
Machlovi, S. I., Neuner, S. M., Hemmer, B. M., Khan, R., Liu, Y., Huang, M., Zhu, J. D., Castellano, J. M., Cai, D., Marcora, E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105615 · Cited by 73
“, 2011), and that APOE genotype is associated with the onset and extent of Aβ deposition in humans (Holtzman et al., 2012).”
BackgroundNon human primate models for Alzheimer’s disease-related research and drug discovery
Dam, D. V., & Deyn, P. P. D. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1271320 · Cited by 77
“quency in human AD brain has been largely attributed to an increase in Aβ1-40-positive plaques [67,72].”
BackgroundAβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
“The precise mechanism for the increased risk associated with APOE ε4 is still not known with certainty, but a leading contender is a role for apoE in the processes of Aβ deposition, aggregation, removal and transport [19].”
InfluentialReassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Role of estrogen in women's Alzheimer's disease risk as modified by APOE
Valencia‐Olvera, A. C., Weng, J. M., Christensen, A., LaDu, M. J., & Pike, C. J. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13209 · Cited by 80
The Importance of Complement-Mediated Immune Signaling in Alzheimer’s Disease Pathogenesis
Batista, A. F., Khan, K. A., Papavergi, M.-T., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020817 · Cited by 65
“Apolipoprotein-E (ApoE) is another molecule that has been linked to AD, atherosclerosis, and other inflammatory conditions [136].”
BackgroundBlum, S., & McCombe, P. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12074 · Cited by 79
“Apoliprotein E (Apo E) is involved in cholesterol transport and is important in neuronal biology (Holtzman et al., 2012).”
BackgroundThe VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
Lau, S.-F., Wu, W., Wong, H. Y., Ouyang, L., Qiao, Y., Xu, J., Lau, J. H.-Y., Wong, C., Jiang, Y., Holtzman, D. M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00491-1 · Cited by 70
Self-citationMicroglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease
Casali, B. T., & Reed-Geaghan, E. G. (2021) · Cells · doi:10.3390/cells10040957 · Cited by 78
Perivascular spaces as a potential biomarker of Alzheimer’s disease
Lynch, M., Pham, W., Sinclair, B., O'Brien, T. J., Law, M., & Vivash, L. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1021131 · Cited by 71
“The E4 allele predisposes one to an increased risk of AD development, four times higher for those who are heterozygous for the APOE4 mutation and twelve times higher for those homozygous for the APOE4 mutation (Holtzman et al., 2012).”
BackgroundThe shared role of cholesterol in neuronal and peripheral inflammation
Hansen, S. B., & Wang, H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108486 · Cited by 72
Nikitidou, E., Khoonsari, P. E., Shevchenko, G., Ingelsson, M., Kultima, K., & Erlandsson, A. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170278 · Cited by 68
“The apoE ε4 allele is the strongest, known genetic risk factor for developing late-onset AD [49] and several investigations have focused on the role of apoE in A pathology [50, 51].”
BackgroundCo-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
Self-citationSavas, J. N., Wang, Y.-Z., DeNardo, L. A., Martinez-Bartolome, S., McClatchy, D. B., Hark, T. J., Shanks, N. F., Cozzolino, K. A., Lavallée-Adam, M., Smukowski, S. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.009 · Cited by 66
Paoletti, F. P., Simoni, S., Parnetti, L., & Gaetani, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094958 · Cited by 80
“In SVD, apoE has been detected in vessel wall lesions [41] and its ε4 allele, which is well-known as the major genetic risk factor for sporadic AD [42], is also associated with the severity of SVD [43].”
BackgroundCurrent Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
“It has been reported that an apolipoprotein E (APOE) isoform influences the risk for AD, and APOE4 is known to be a strong genetic risk factor [19].”
BackgroundAlzheimer's Disease and Sleep–Wake Disturbances: Amyloid, Astrocytes, and Animal Models
Vanderheyden, W. M., Lim, M. M., Musiek, E. S., & Gerstner, J. R. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1135-17.2017 · Cited by 66
Chernick, D., Ortiz-Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 62
Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 69
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
“APOE plays critical roles in cholesterol transport, neuroplasticity, and inflammation.(12) APOE regulates Aβ metabolism directly through binding and clearance of Aβ(13) and indirectly via the LRP1 receptor.”
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
“Brain cholesterol is isolated from the systemic circulation [201].”
Jia, J., Xu, J. L., Liu, J., Wang, Y., Wang, Y., Cao, Y., Guo, Q., Qu, Q.-M., Wei, C., Wei, W., et al. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00701-z · Cited by 63
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Self-citationWalhovd, K. B., Fjell, A. M., & Espeseth, T. (2014) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12120 · Cited by 66
Sorting receptor sortilin—a culprit in cardiovascular and neurological diseases
Carlo, A.-S., Nykjaer, A., & Willnow, T. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1152-3 · Cited by 56
“ApoE-bound Aβ is cleared from the ISF by multiple cell types, including neurons, astrocytes, as well as pericytes that line the brain vasculature, collectively reducing the amyloidogenic burden in the brain [46].”
BackgroundA role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
“LRP4 is a core member of the LDLR family, which have been implicated in AD pathogenesis by modulating Ab metabolism (Holtzman et al., 2012; Lane-Donovan and Herz, 2017).”
BackgroundLee, H., Aylward, A. J., Pearse, R. V., Lish, A. M., Hsieh, Y.-C., Augur, Z. M., Benoit, C. R., Chou, V., Knupp, A., Pan, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112994 · Cited by 58
ApoE ε4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60
Wendelken, L. A., Jahanshad, N., Rosen, H. J., Busovaca, E., Allen, I. E., Coppola, G., Adams, C., Rankin, K. P., Milanini, B., Clifford, K. M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001091 · Cited by 62
“ApoE is critical to neuronal health, including synaptic plasticity, neuroprotection, and transport of cholesterol and other lipids crucial to myelin integrity and may play a role in mediating inflammation in the CNS.8,39 Future studies of A-beta imaging or levels of CSF A-beta might elucidate whether effects of ApoE o…”
BackgroundDong, H. K., Gim, J., Yeo, S. H., & Kim, H. (2016) · Gene · doi:10.1016/j.gene.2016.10.022 · Cited by 66
Nirzhor, S. S. R., Khan, R. I., & Neelotpol, S. (2018) · Biomolecules · doi:10.3390/biom8030093 · Cited by 61
Bilousova, T., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C., Hatami, A., et al. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 54
Guo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 62
Larramona-Arcas, R., González-Arias, C., Perea, G., Gutiérrez, A., Vitorica, J., García-Barrera, T., Gómez-Ariza, J. L., Pascua-Maestro, R., Ganfornina, M. D., Kara, E., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00382-8 · Cited by 56
“Astrocytes can also take up lipoproteins, as they express APOE receptors such as the LRP1 receptor [25].”
BackgroundChen, Y. Q., Troutt, J. S., & Konrad, R. J. (2014) · Lipids · doi:10.1007/s11745-014-3895-6 · Cited by 56
Interactions of metals and Apolipoprotein E in Alzheimer’s disease
Xu, H. J., Finkelstein, D. I., & Adlard, P. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00121 · Cited by 66
“…have less full-length ApoE but more ApoE fragments in brain parenchyma and plasma than APOE2 carriers (Riddell et al., 2008; Gupta et al., 2011); with decreased ApoE levels in APOE4 carriers considered an important factor for AD onset/development (Verghese et al., 2011; Holtzman et al., 2012).”
BackgroundApolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease
Wolf, A. B., Valla, J., Bu, G., Kim, J., LaDu, M., Reiman, E. M., & Caselli, R. J. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt204 · Cited by 57
“play of apoE with β-amyloid, and this topic has been recently reviewed [2].”
BackgroundSelf-citationArea-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
“cholesterol and other lipids through the bloodstream, as well as within the brain (1-3).”
BackgroundApoE4 attenuates autophagy via FoxO3a repression in the brain
Sohn, H.-Y., Kim, S.-I., Park, J.-Y., Park, S.-H., Koh, Y. H., Kim, J., & Jo, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-97117-6 · Cited by 54
The application of nanotechnology in treatment of Alzheimer’s disease
Cao, Y., & Zhang, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1042986 · Cited by 59
“LRP1 is likewise an APOE and APP receptor (Holtzman et al., 2012).”
BackgroundMolecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bin Bashar, M. F., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 53
“Furthermore, diverse mechanisms including APOE isoform-dependent, lipidation-status-dependent, and concentration-dependent mechanisms [112, 170] are responsible for complicating these events.”
BackgroundInfluentialMaftei, M., Thurm, F., Schnack, C., Tumani, H., Otto, M., Elbert, T., Kolassa, I.-T., Przybylski, M., Manea, M., & von Arnim, C. A. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068996 · Cited by 55
“An elevated antibody production would be expected in response to Ab accumulation, which is either due to deficient clearance mechanisms [68,69] or to an increased formation of Ab peptides.”
BackgroundApolipoprotein E: Remarkable Protein Sheds Light on Cardiovascular and Neurological Diseases
Mahley, R. W. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.255695 · Cited by 53
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 57
“modulation of Alzheimer’s disease (AD) development is still not completely understood, emerging data suggest that APOE contributes to AD pathogenesis through a wide range of biological functions, including amyloid beta (Aβ)-dependent pathway and Aβ-independent pathway [2–4].”
BackgroundMah, D., Zhao, J., Liu, X.-Y., Zhang, F.-M., Liu, J., Wang, L.-C., Linhardt, R., & Wang, C.-Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671458 · Cited by 37
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt135 · Cited by 48
“Aβ, amyloid-β peptide; AD, Alzheimer’s disease; apoE, apolipoprotein E; APP, amyloid precursor protein; BBB, blood brain barrier; CNS, central nervous system; EOAD, early onset Alzheimer’s disease; LDL, low-density lipoprotein; LDLR, LDL receptor; LOAD, late onset Alzheimer’s disease; LRP, LDL receptorrelated protein;…”
InfluentialLebeau, P. F., Al‐Hashimi, A., Sood, S. K., Lhoták, Š., Yu, P., Gyulay, G., Paré, G., Chen, S. R. W., Trigatti, B. L., Prat, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744235 · Cited by 57
“Moreover, we also observed a significant reduction in circulating HDL levels (Fig.”
BackgroundInfluentialApolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway
Yin, J., Nielsen, M., Carcione, T., Li, S., & Shi, J. (2019) · Aging · doi:10.18632/aging.102516 · Cited by 58
“Mounting evidence indicates that ApoE4 may interfere with Aβ clearance [2, 3].”
BackgroundChernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
Pontifex, M. G., Martinsen, A., Saleh, R. N. M., Harden, G., Tejera, N., Müller, M. M., Fox, C., Vauzour, D., & Minihane, A. M. (2021) · The FASEB Journal · doi:10.1096/fj.202002621rr · Cited by 55
Alzheimer’s genes in microglia: a risk worth investigating
Sudwarts, A., & Thinakaran, G. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00679-4 · Cited by 44
“Lipidation of APOE affects its conformation, subsequently affecting binding to receptors and to Aβ (reviewed in [196]).”
BackgroundPontifex, M., Vauzour, D., & Minihane, A.-M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.017 · Cited by 47
Innate immunity and cellular senescence: The good and the bad in the developmental and aged brain
Santoro, A., Spinelli, C. C., Martucciello, S., Nori, S. L., Capunzo, M., Puca, A. A., & Ciaglia, E. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0118-003r · Cited by 50
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Le Guen, Y., Raulin, A.-C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., Chen, A., Kennedy, G., Kuchenbecker, L., O’Leary, J. P., et al. (2023) · JAMA · doi:10.1001/jama.2023.0268 · Cited by 50
Self-citationSmall molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway
Fan, J., Zhao, R. Q., Parro, C., Zhao, W., Chou, H.-Y., Robert, J., Deeb, T. Z., Raynoschek, C., Barichievy, S., Engkvist, O., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081851 · Cited by 50
“The apoE gene, the primary lipid carrier in the CNS, is the most highly associated susceptibility locus for late onset AD and also plays major roles in the metabolism of A peptides as well as in inflammation (1, 2).”
BackgroundDeming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
“two ε4 alleles confer 8- to 12-fold increased risk [5,6].”
BackgroundApoE and cerebral insulin: Trafficking, receptors, and resistance
Rhea, E. M., Raber, J., & Banks, W. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104755 · Cited by 47
Jia, Y., Wang, N., Zhang, Y., Xue, D., Lou, H., & Liu, X. (2020) · Aging and disease · doi:10.14336/ad.2019.0519 · Cited by 46
“ABCA1 regulates levels of ApoE and ApoE lipidation, while ApoE is regarded as a chaperone for Aβ, affecting its clearance and aggregate [119].”
BackgroundParanjpe, M. D., Belonwu, S., Wang, J. K., Oskotsky, T., Gupta, A., Taubes, A., Zalocusky, K. A., Paranjpe, I., Glicksberg, B. S., Huang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735611 · Cited by 49
“org/ 212 72 (34) 29/43 (40) 22/50 (31) 54/86 (39) 19/121 (14)”
Ogama, N., Endo, H., Satake, S., Niida, S., Arai, H., & Sakurai, T. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12807 · Cited by 49
“Moreover, the apolipoprotein ε4 genotype causes vascular dysfunction by affecting Aβ clearance in the brain.(27) Thus, AD-related pathology is thought to be involved in the development of WMH.”
BackgroundYoon, C., Van Niekerk, E. A., Henry, K., Ishikawa, T., Orita, S., Tuszynski, M. H., & Campana, W. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478552 · Cited by 46
“LRP1 alsomodulates amyloid precursor protein processing through interaction with apolipoprotein E (46, 3).”
BackgroundTargeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M., Pihlajamäki, J., Soininen, H., & Hiltunen, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 46
“The LDL receptor family includes the core members LDL receptor, LDL receptor-related protein (LPR1), LDL receptorrelated protein 1B (LRP1B), megalin/LRP2, the very low-density lipoprotein receptor (VLDLR), ApoE receptor 2 (ApoER2/LRP8), LRP4/MEGF7, and more distantly related members LRP5, LRP6, and sorting protein-rel…”
BackgroundInhibition of A1 Astrocytes and Activation of A2 Astrocytes for the Treatment of Spinal Cord Injury
Wang, J., Cheng, C., Liu, Z., Lin, Y., Yang, L., Zhang, Z., Sun, X., Zhou, M., Jing, P., & Zhong, Z. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03820-9 · Cited by 53
Advances in high-density lipoprotein physiology: surprises, overturns, and promises
Constantinou, C., Karavia, E. A., Xepapadaki, E., Πετροπούλου, Π.-Ι., Παπακώστα, Ε., Karavyraki, M., Zvintzou, E., Theodoropoulos, V., Filou, S., Hatziri, A., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2015 · Cited by 53
“interaction with A ; instead, it has been shown to compete with A for the same clearance pathways (71, 78, 124, 187).”
BackgroundKoriath, C., Lashley, T., Taylor, W., Druyeh, R., Dimitriadis, A., Denning, N., Williams, J., Warren, J. D., Fox, N. C., Schott, J. M., et al. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.010 · Cited by 45
“Multiple lines of evidence suggest that ApoE4 risk in AD principally relates to enhanced and accelerated cerebral Ab pathology [4].”
BackgroundCDT2‐controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease
Huang, F., Wang, M., Liu, R., Wang, J., Schadt, E., Haroutunian, V., Katsel, P., Zhang, B., & Wang, X. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.013 · Cited by 47
“A large amount of evidence has demonstrated that in addition to increasing disease risk, apoE 4 stimulating the transcription factor AP-1 enhances transcription of APP and Ab levels and thereby accelerates early seeding of amyloid pathology [54,55], while apoE 4 markedly exacerbates tau-mediated neurodegeneration in a…”
BackgroundAmyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients
Karakatsani, M. E., Ji, R., Murillo, M. F., Kugelman, T., Kwon, N., Lao, Y.-H., Liu, K., Pouliopoulos, A. N., Honig, L. S., Duff, K. E., et al. (2023) · Theranostics · doi:10.7150/thno.79898 · Cited by 40
“LDLr deficiency leads to learning difficulties, impaired spatial cognition, ApoE increase [51] and amyloid deposits while overexpression of LDLr has been associated with decreased ApoE levels and amyloid inhibition [52].”
BackgroundCudaback, E., Yang, Y., Montine, T. J., & Keene, C. D. (2015) · Glia · doi:10.1002/glia.22732 · Cited by 47
“Secreted apoE is known to bind cell-surface receptors (Holtzman et al., 2012), thereby initiating signal transduction cas- cades that subsequently alter a variety of cellular processes, including cell motility (Cudaback et al., 2011) and chemical secretion (Keene et al., 2011; LaDu et al., 2001).”
BackgroundKempf, S. J., Janik, D., Barjaktarovic, Z., Braga-Tanaka, I., Tanaka, S., Neff, F., Saran, A., Larsen, M. R., & Tapio, S. (2016) · Oncotarget · doi:10.18632/oncotarget.12376 · Cited by 47
“ApoE deficient C57BL/6 mice were used as an AD model; the APOE genotype is known as the major genetic risk factor for AD in human supressing synaptic plasticity, lipid transport and metabolism [19].”
MethodAlcendor, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051490 · Cited by 48
Homann, J., Osburg, T., Ohlei, O., Dobricic, V., Deecke, L., Bos, I., Vandenberghe, R., Gabel, S., Scheltens, P., Teunissen, C. E., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.840651 · Cited by 46
Identification of apolipoprotein using feature selection technique
Tang, H., Zou, P., Zhang, C., Chen, R., Chen, W., & Lin, H. (2016) · Scientific Reports · doi:10.1038/srep30441 · Cited by 46
Regulation of membrane NMDA receptors by dynamics and protein interactions
Petit‐Pedrol, M., & Groc, L. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202006101 · Cited by 50
Microglial Lipid Biology in the Hypothalamic Regulation of Metabolic Homeostasis
Folick, A., Koliwad, S. K., & Valdearcos, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.668396 · Cited by 52
Browne, R. W., Weinstock‐Guttman, B., Horáková, D., Zivadinov, R., Bodziak, M. L., Tamano-Blanco, M., Badgett, D., Týblová, M., Vaněčková, M., Seidl, Z., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307106 · Cited by 46
Peroxisome Proliferator-activated Receptors and Alzheimer's Disease: Hitting the Blood–Brain Barrier
Zolezzi, J. M., & Inestrosa, N. C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8435-5 · Cited by 49
“On the other hand, ApoE isoform 2 (ApoE2) has shown to act as a protective factor, reducing the risk of developing AD [54, 68–70].”
BackgroundRezeli, M., Zetterberg, H., Blennow, K., Brinkmalm, A., Laurell, T., Hansson, O., & Marko-Varga, G. (2015) · EuPA Open Proteomics · doi:10.1016/j.euprot.2015.07.012 · Cited by 43
Singh, A. K., Mishra, G., Maurya, A., Awasthi, R., Kumari, K., Thakur, A., Rai, A., Rai, G. K., Sharma, B., Kulkarni, G. T., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190903102822 · Cited by 47
Multitasking: Dual Leucine Zipper–Bearing Kinases in Neuronal Development and Stress Management
Jin, Y., & Zheng, B. (2019) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062644 · Cited by 53
“The ApoE4 allele increases risk for AD, whereas the ApoE2 allele is protective against AD (Holtzman et al. 2012, Strittmatter et al. 1993).”
BackgroundMicrophysiological systems for recapitulating physiology and function of blood-brain barrier
Seo, S., Kim, H., Sung, J. H., Choi, N., Lee, K., & Kim, H. N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119732 · Cited by 47
Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon?
Hartmann, H., Ho, W. Y., Chang, J., & Ling, S. (2022) · The FEBS Journal · doi:10.1111/febs.16175 · Cited by 45
Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes
Xu, H. J., Perreau, V. M., Dent, K. A., Bush, A. I., Finkelstein, D. I., & Adlard, P. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150797 · Cited by 47
“LDLR, LRP1 (low density lipoprotein receptor-related protein 1), VLDLR (very low-density lipoprotein receptor), and ApoER2 (ApoE receptor 2) are the four main receptors within this family [21].”
LilrB3 is a putative cell surface receptor of APOE4
Zhou, J., Wang, Y., Huang, G., Yang, M., Zhu, Y., Jin, C., Jing, D., Ji, K., & Shi, Y. (2023) · Cell Research · doi:10.1038/s41422-022-00759-y · Cited by 52
“This is also true for a number of other cell surface receptors.(1,62,86,87) In contrast to TREM2, the LilrB/PirB family receptors contain the ITIMs on the intracellular side, binding of two APOE4 molecules to two LilrB3 receptors effectively brings their respective ITIMs to close proximity.”
BackgroundRoles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 48
Links between copper and cholesterol in Alzheimer's disease
Hung, Y. H., Bush, A. I., & Fontaine, S. L. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00111 · Cited by 46
“Apolipoprotein E (ApoE), a 299-amino acid glycoprotein, is the primary apolipoprotein involved in the regulation of lipid transport in both the plasma and the CSF [reviewed in Hauser et al. (2011), Holtzman et al. (2012) and Leduc et al. (2010)].”
BackgroundAPOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease
Sun, X., Dong, C., Levin, B., Crocco, E., Loewenstein, D., Zetterberg, H., Blennow, K., Wright, C. B., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.003 · Cited by 42
“APOE ε4 carriers with AD or amnestic mild cognitive impairment (MCI) have lower b-amyloid 42 (Ab42), elevated total tau (t-tau), and phospho-tau (p-tau) in cerebrospinal fluid (CSF), compared to APOE ε4 noncarriers [2].”
Retinal glial changes in Alzheimer's disease – A review
Fernández‐Albarral, J. A., Salobrar‐García, E., Martínez-Páramo, R., Ramirez, A. I., de Hoz, R., Ramirez, J. M., & Salazar, J. J. (2018) · Journal of Optometry · doi:10.1016/j.optom.2018.07.001 · Cited by 50
“In the CNS, APOE is expressed predominantly by astrocytes but also by microglia.(4,5) Pathologically, AD is characterized by deposits of extracellular plaques of -amyloid (A ) peptide or senile plaques and neurofibrillary tangles (NFTs) resulting from intracellular aggregates of hyperphosphorylated tau protein.”
BackgroundMahley, R. W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102684 · Cited by 43
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 47
The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease
Sabbagh, M. N., Malek‐Ahmadi, M. H., Dugger, B. N., Lee, K., Sue, L. I., Serrano, G. E., Walker, D. G., Davis, K. J., Jacobson, S. A., & Beach, T. G. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-44 · Cited by 44
“[26] highlight the importance of ApoE lipidation status as it relates to amyloid deposition stating that decreases in ApoE lipidation lead to increased amyloid deposition through increased fibrillization of Aβ.”
BackgroundNeuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
“, 2001); ApoE binds to esterified cholesterol via the low-density lipoprotein receptor-associated protein (LPR) pathway after perceived entry into neurons (Holtzman et al., 1995).”
BackgroundSex differences in gene expression patterns associated with the APOE4 allele
Hsu, M., Dedhia, M., Crusio, W., & Delprato, A. (2019) · F1000Research · doi:10.12688/f1000research.18671.1 · Cited by 44
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100176 · Cited by 44
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 42
The silence of the fats: A MAM’s story about Alzheimer
Agrawal, R. R., Montesinos, J., Larrea, D., Área-Gómez, E., & Pera, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105062 · Cited by 47
A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease
Yang, A., Liu, C., Wu, J., Kou, X., & Shen, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173950 · Cited by 42
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.